Navigation Links
Valeant Announces Successful Results From Phase III Onychomycosis Trials
Date:12/16/2011

MISSISSAUGA, Ontario, Dec. 16, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced successful results from two large international Phase 3 studies of its topical investigational drug {efinaconazole (IDP-108)} product for the treatment of mild to moderate onychomycosis of the toenail. In both the studies, the investigational drug product was found to be statistically superior (p<0.001) to placebo for all primary and secondary endpoints. It was found to be generally safe and well tolerated.

Efinaconazole is an investigational antifungal drug belonging to the triazole family. The investigational drug product has not been found by the U.S. Food and Drug Administration (FDA) to be safe or effective for the treatment of mild to moderate onychomycosis of the toenail and may not be sold or promoted in the United States unless the FDA has approved a new drug application. Similar restrictions apply in other countries. 

Valeant holds an exclusive license from Kaken Pharmaceutical Co., Ltd., to commercialize efinaconazole in North America, Central America, South America and the European Union.

About Onychomycosis

Onychomycosis (also known as "dermatophytic onychomycosis" and "tinea unguium") is a fungal infection that affects the nail and nail bed. The prevalence of onychomycosis is about 6-8% in the adult population. It is the most common disease of the nail and constitutes about a half of all nail abnormalities. Without treatment, the nails thicken and cause localized pressure-related pain. Dermatophytes are the primary fungi that cause onychomycosis.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

To the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

These forward-looking statements relate to, among other things, the successful approval and commercialization of IDP-108.  Forward-looking statements can generally be identified by the use of words such as "believe", "anticipate", "expect", "estimate", "intend", "continue", "plan", "project", "will", "may", "should", "could", "would", "target", "potential" and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, the successful approval and commercialization of IDP-108, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators ("CSA"). 

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc.
2. Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik
3. Valeant Pharmaceuticals to Syndicate Incremental Term Loans
4. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
5. Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization
6. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
7. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
8. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
9. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
10. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
11. Valeant Pharmaceuticals to Present at Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
(Date:9/9/2017)... ... ... – Monday, September 18 th .The Brain Tumor Foundation (BTF) begins ... the public.Where:  BTF,s Mobile MRI Unit – a ... Washington, D.C.What:BTF brings its nationwide initiative, the Road to Early Detection Sponsor-A-City ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... SignatureCare Emergency Center ... The $1000 student scholarship is awarded each semester to a deserving student. Congratulations ... who is a medical student at Arizona State University with a 3.63 GPA. ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Coleman Institute, a ... an affiliate in Minneapolis-St. Paul, MN, Dr. Adam Locketz. Dr. Locketz will be ... aftercare planning through his Timewise Medical practice in the twin cities. , ...
(Date:9/25/2017)... ... 25, 2017 , ... SyncDog, Inc., the leading ... 3.0, will be available in a managed cloud services model, available from its ... several new enhancements including support for caller ID and network sharing for remote ...
(Date:9/25/2017)... ... 25, 2017 , ... FDAnews Expert Insight Series:, Device Regulation ... – 3:00 p.m. ET, http://www.fdanews.com/deviceregulation      , FDA Commissioner Scott ... short months:, ,     The first device recall over cybersecurity (a ...
(Date:9/25/2017)... SC (PRWEB) , ... September 25, 2017 , ... The ... efforts in helping those with disabilities. Each year the award is given to those ... people with disabilities live their best lives in communities of their choosing. Recent recipients ...
Breaking Medicine News(10 mins):